Introduction {#j_jomb-2017-0051_s_001}
============

Vitamin B12 (cobalamin) deficiency is a worldwide health problem with variable prevalence ([@j_jomb-2017-0051_ref_001]). In Jordan, vitamin B12 deficiency has been estimated at 16--50%, with higher prevalence in the elderly above 55 years ([@j_jomb-2017-0051_ref_002], [@j_jomb-2017-0051_ref_003], [@j_jomb-2017-0051_ref_004]). The most common symptoms of vitamin B12 deficiency are hematological and/or neurological disorders ([@j_jomb-2017-0051_ref_005], [@j_jomb-2017-0051_ref_006]). Therefore, some risk factors of vitamin B12 deficiency have been investigated including lifestyle, age, and ethnic origin ([@j_jomb-2017-0051_ref_007], [@j_jomb-2017-0051_ref_008], [@j_jomb-2017-0051_ref_009], [@j_jomb-2017-0051_ref_010], [@j_jomb-2017-0051_ref_011], [@j_jomb-2017-0051_ref_012], [@j_jomb-2017-0051_ref_013]). Moreover, genetic predisposition was demonstrated in vitamin B12 deficiency. For instance, mutations and polymorphisms in transport proteins such as transcobalamin TCN, gastric intrinsic factor GIF and metabolic enzymes such as methylenetetrahydrofolate reductase MTHFR have been associated with vitamin B12 deficiency. Other vitamin-B12 related abnormalities like homocysteinemia and neural tube defect (NTD) have also been associated with genetic variants in these genes ([@j_jomb-2017-0051_ref_013], [@j_jomb-2017-0051_ref_014], [@j_jomb-2017-0051_ref_015], [@j_jomb-2017-0051_ref_016], [@j_jomb-2017-0051_ref_017], [@j_jomb-2017-0051_ref_018], [@j_jomb-2017-0051_ref_019], [@j_jomb-2017-0051_ref_020], [@j_jomb-2017-0051_ref_021], [@j_jomb-2017-0051_ref_022]).

MTHFR catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate; the latter is required for the conversion of homocysteine to methionine by methionine synthase (MS). MS catalytic function is dependent on vitamin B12 ([@j_jomb-2017-0051_ref_023]). More than 40 mutations have been identified in the *MTHFR* gene in individuals diagnosed with homocystinuria, and several polymorphisms in the *MTHFR* gene have been associated with an increased risk of neural tube defects (NTD) and anencephaly ([@j_jomb-2017-0051_ref_016]). Moreover, the MTHFR gene polymorphisms have also been linked to cardiovascular diseases, stroke, psychiatric disorders, and certain types of cancer ([@j_jomb-2017-0051_ref_024], [@j_jomb-2017-0051_ref_025], [@j_jomb-2017-0051_ref_026], [@j_jomb-2017-0051_ref_027], [@j_jomb-2017-0051_ref_028]). In particular, the c.677C\>T variant (NM_005957.4: c.677C\>T, rs1801133) is the most common genetic variant in homocystinuria ([@j_jomb-2017-0051_ref_024], [@j_jomb-2017-0051_ref_029]). The c.677C\>T variant encodes a thermolabile form of the MTHFR which is less active at high temperatures ([@j_jomb-2017-0051_ref_030]). Another MTHFR variant, 1298A\>C (NM_005957.4: c.1286A\>C, rs1801131), does not cause increased homocysteine levels in heterozygous or homozygous individuals, but combined heterozygous genotypes of c.1298A\>C and c.677C\>T result in an outcome similar to c.677C\>T homozygous individuals ([@j_jomb-2017-0051_ref_031], [@j_jomb-2017-0051_ref_032], [@j_jomb-2017-0051_ref_033]). Recent studies have associated the c.677C\>T variant with vitamin B12 deficiency and homocystinuria ([@j_jomb-2017-0051_ref_013], [@j_jomb-2017-0051_ref_014], [@j_jomb-2017-0051_ref_015]). In the present case-control study, we investigated the association of the c.677C\>T and c.1298A\>C variants in the *MTHFR* gene with vitamin B12 deficiency in a subset of the Jordanian population living in the northern part of the country.

Patients and Methods {#j_jomb-2017-0051_s_002}
====================

One hundred individuals (45 males and 55 females) diagnosed with B12 deficiency (B12 \< 200 mg/mL) were enrolled in this study from hospitals in northern Jordan, with an average age of 37 years. The control group included 100 individuals (53 males and 47 females) with an average age of 32 years. Blood samples (3 mL) were collected from participants in EDTA tubes and stored at 4 °C until the time of DNA extraction. Demographics and clinical information were obtained from hospital clinical records and questionnaires filled in by participants. All participants were aware of the scope of the study and informed consents were obtained according to the guidelines of the Research Ethics Committee at Yarmouk University.

Genomic DNA extraction {#j_jomb-2017-0051_s_002_s_001}
----------------------

The phenol-chloroform extraction method was used for genomic DNA extraction. Briefly, 200 μL of blood was mixed with 500 μL of extraction buffer (0.01 mol/L Tris-HCl, 0.1 mol/L NaCl, 0.01 mol/L EDTA, 2% SDS and 0.39 mol/L DTT) and 20 μL of 20 mg/mL proteinase K, followed by incubation for 2 hours at 56 °C, then 500 μL of phenol: chloroform: isoamyl alcohol were mixed vigorously and spun at 14,000 g for 5 minutes. The aqueous layer was transferred to an Eppendorf tube, mixed with phenol: chloroform: isoamyl alcohol and centrifuged at 14,000 g for 5 minutes. The last aqueous portion was mixed with one mL of ice-cold absolute ethanol and centrifuged at 14,000 g for 5 minutes. The DNA pellet was washed twice with 70% ethanol and eluted with 100 μL of TE buffer and stored at --20 °C until further use.

PCR amplification of the MTHFR target sequence {#j_jomb-2017-0051_s_002_s_002}
----------------------------------------------

Polymerase chain reaction was performed by using specific primers that target the sequences of interest in the MTHFR gene. For the c.677C\>T genotypes, the following pairs of primers were used: (F-5'CCT TGA ACA GGT GGA GGC CAG-3' and R-5'GCG GTG AGA GTG GGG TGG AG-3'). For the 1298A\>C genotyping, the following pairs of primers were used: (5'-CTT TGG GGA GCT GAA GGA CTA CTA-3' and 5'-CAC TTT GTG ACC ATT CCG GTT TG-3'). The amplification was performed in 25 μL final volume by using Taq 2X Master Mix (New England BioLabs, USA) according to the manufacturer's instructions. Briefly, 3 μL of DNA were added to 12.5 μL of 2X master mix with a final concentration of primers 0.2 μmol/L and completed to 25 μL by adding dd.H~2~O. PCR conditions were as follows: initial denaturation at 95 °C for 5 minutes, 35 cycles of denaturation at 95 °C for 1 minute, annealing (65 °C for the c.677C\>T and 72 °C for the 1298A\>C) for 30 seconds and extension at 72 °C for 1 minute, followed by 3 minutes of final extension at 72 °C.

Restriction fragment length polymorphism (RFLP) {#j_jomb-2017-0051_s_002_s_003}
-----------------------------------------------

For the *MTHFR* c.677C\>T genotyping, restriction enzyme digestion was performed by using Hinf I restriction enzyme (New England BioLabs, USA). Restriction enzyme digestion tube contained 8 μL of PCR product, 4 units of Hinf I, 1 X Hinf I buffer, 0.1 mg/mL of BSA and H~2~O up to a final volume of 20 μL, followed by incubation at 37 °C for 90 minutes. Inactivation step was performed by heating the mixture at 65 °C for 15 minutes. Products of the RFLP digestion were resolved by 3% agarose gel at 10 V/cm current for 1.5 hours (*[Figure 1](#j_jomb-2017-0051_fig_001){ref-type="fig"}*).

![RFLP-PCR products of the MTHFR-c.677C\>T genotypes by Hinf1. Lane 1: 100 bp DNA ladder, lanes 2-4: homozygous CC genotype, lanes 5-7: heterozygous CT genotype and lanes 8-10: recessive genotype TT.](jomb-37-141-g001){#j_jomb-2017-0051_fig_001}

DNA sequencing of the 1298A\>C genotype {#j_jomb-2017-0051_s_002_s_004}
---------------------------------------

Sanger DNA sequencing of the PCR products of the amplified target of the MTHFR 1298A\>C genotype was performed at GENWIZ, USA.

Statistical Analysis {#j_jomb-2017-0051_s_002_s_005}
--------------------

Chi-square and Fisher's exact test analyses were used for the calculation of p value, odds ratio (OR), and 95% confidence interval (CI) and Hardy--Weinberg Equilibrium (HWE) evaluation. GraphPad Prism-6 software was used for statistical analysis, p \< 0.05 cut off was considered significant.

Results {#j_jomb-2017-0051_s_003}
=======

MTHFR c.677C\>T and c. 1298A\>C genotypic frequencies {#j_jomb-2017-0051_s_003_s_001}
-----------------------------------------------------

In the samples analyzed, DNA sequencing for the c.677C\>T polymorphic site identified the genotypic frequencies of CC (41%), CT (45%) and TT (14%). In addition, frequencies of homozygous AA, heterozygous AT and homozygous TT genotypes for the 1298A\>C variants were 34%, 59% and 7%, respectively (*[Table I](#j_jomb-2017-0051_tab_001){ref-type="table"}*). There was no digression from the Hardy-Weinberg equilibrium (HWE) for the c.677C\> T variants (*[Table II](#j_jomb-2017-0051_tab_002){ref-type="table"}*). On the other hand, frequencies of the 1298A\>C variants showed deviation from the HWE (*p* \< 0.05) *([Table III](#j_jomb-2017-0051_tab_003){ref-type="table"}*).

###### 

MTHFR Genotypes frequencies according to the level of vitamin B12.

                                 B12 Deficient   Control        *p* Value       OR             95% CI         
  ------------------------------ --------------- -------------- --------------- -------------- -------------- --
                                 B12 (mg/mL)     142.31±24.09   441.76±179.06   *2.84E-39\**                  
  Age (years)                    38.04±11.69     32.71±15.04                                                  
  Male n (%)                     53 (53 %)       45 (45 %)      *0.258*         1.378          0.79--2.4      
  Female n (%)                   47 (47 %)       55 (55 %)                                                    
  MTHFR 677C\>T                  TT              21             7               *0.015\**                     
  CT                             43              47                                                           
  CC                             36              46                                                           
  C                              115             139            *0.017\**       1.684          1.116--2.542   
  T                              85              61                                                           
  MTHFR 1298A\>C                 AA              36             32              *0.662*                       
  AC                             56              62                                                           
  CC                             8               6                                                            
  A                              128             126            *1.000*         1.016          0.677--1.524   
  C                              72              74                                                           
  *MTHFR* 677C\>T And 1298A\>C   CC/AA           9              13              *0.173*                       
  CC/AC                          23              29                                                           
  CC/CC                          4               4                                                            
  CT/AA                          19              18                                                           
  CT/AC                          23              27                                                           
  CT/CC                          1               2                                                            
  TT/AA                          8               1                                                            
  TT/AC                          10              6                                                            
  TT/CC                          3               0                                                            

\* p value \< 0.05

###### 

MTHFR c.677C\>T Genotypes frequencies in association with B12 level and age.

                             Total       TT          CT          CC          p value
  -------------------------- ----------- ----------- ----------- ----------- ----------------
  *MTHFR* genotype 677C\>T   n=200       n = 28      n = 90      n = 82      *0.68 (HWE)\**
  Age (year)                 35.4±13.7   43.7±10.9   36.4±14.5   31.4±11.9   0.007\*\*
  Males                      98 (49%)    15 (54 %)   35 (39%)    48 (59%)    0.6
  B12 (\< 200 mg/mL)         100 (50%)   21          43          36          0.015\*\*
  B12 (≥ 200 mg/mL)          100 (50%)   7           47          46          

\*Hardy-Weinberg equilibrium, \*\*p value \< 0.05

###### 

MTHFR c.1298A\>C Genotypes of frequencies in association with B12 level and age.

                            Total         AA            AC            CC            p value
  ------------------------- ------------- ------------- ------------- ------------- ----------------
  MTHFR 1298A\>C genotype   n = 200       n = 68        n = 118       n = 14        0.0001 (HWE)\*
  Age (year)                35.4 ± 13.7   35.1 ± 13.9   34.9 ± 13.2   40.9 ± 16.8   0.243
  Males                     99 (50%)      29 (43 %)     66 (56%)      4 (29%)       0.06
  B12 (\< 200 mg/mL)        100 (50%)     36            56            8             0.662
  B12 (≥ 200 mg/mL)         100 (50%)     32            62            6             

\*Hardy-Weinberg equilibrium

MTHFR c.677C\>T and c. 1298A\>C genotypes distribution in B12 deficient individuals {#j_jomb-2017-0051_s_003_s_002}
-----------------------------------------------------------------------------------

DNA sequencing and RFLP analysis for the c.677C\>T variants showed that the frequency of homozygous CC genotype was 36/100 (36%) in the B12 deficient individuals. In addition, frequencies of heterozygous CT and homozygous TT genotypes were 43/100 (43%) and 21/100 (21%), respectively. On the other hand, analysis of the control group showed the following frequencies for the c.677C\> T variants: homozygous CC genotype 46/100 (46%), heterozygous CT and homozygous TT genotypes 47/100 (47%) and 7/100 (7%), respectively. Hence, the c.677C\>T genotypes frequencies distribution revealed a significant difference in individuals with vitamin B12 compared to controls. Particularly, the frequency of the homozygous TT genotype is significantly higher in B12 deficient individuals in comparison with the control group (*X^2^* = 8.397, *p = 0.0150)*. Moreover, T allele frequency showed significant association with vitamin B12 deficiency in the study population (OR = 1.684, 95% CI: 1.116 to 2.542, *p* = *0.017*). The results are shown in *[Table I](#j_jomb-2017-0051_tab_001){ref-type="table"}*.

Conversely, B12 deficient individuals did not show any significant difference in the genotype frequencies distribution for the 1298A\>C variant in comparison with the control group (*X^2^* = 0.83, *p = 0.662)*. The frequency of homozygous AA genotype for the 1298A\>C variants was 36/100 (36%) in the B12 deficient individuals. In addition, heterozygous AC and homozygous CC genotypes were 56/100 (56%) and 8/100 (8%), respectively. In the control group, frequencies of homozygous AA genotype were 32/100 (32%), heterozygous AC and homozygous CC genotypes 62/100 (62%) and 6/100 (6%), respectively, as shown in *[Table I](#j_jomb-2017-0051_tab_001){ref-type="table"}* and *[Table III](#j_jomb-2017-0051_tab_003){ref-type="table"}*.

Interestingly, our results showed a significant association between the c.677C\>T genotypes and the age at onset of vitamin B12 deficiency (*p* = 0.007). In particular, the homozygous TT genotype or T allele is more frequent in older individuals with vitamin B12 deficiency (*[Table II](#j_jomb-2017-0051_tab_002){ref-type="table"}*).

Discussion {#j_jomb-2017-0051_s_004}
==========

Vitamin B12 deficiency is a diet-related and slowly developing disorder. Consequently, low levels of vitamin B12 are associated with neurological and hematological disorders such as neural tube defects, cardiovascular diseases, dementia, as well as some types of cancer ([@j_jomb-2017-0051_ref_008], [@j_jomb-2017-0051_ref_016], [@j_jomb-2017-0051_ref_028], [@j_jomb-2017-0051_ref_034]). However, genetic predisposition to vitamin B12 deficiency has been demonstrated in various studies ([@j_jomb-2017-0051_ref_014], [@j_jomb-2017-0051_ref_015], [@j_jomb-2017-0051_ref_016], [@j_jomb-2017-0051_ref_017], [@j_jomb-2017-0051_ref_018], [@j_jomb-2017-0051_ref_019], [@j_jomb-2017-0051_ref_020], [@j_jomb-2017-0051_ref_021], [@j_jomb-2017-0051_ref_022]). For in stance, vitamin B12 deficiency has been demonstrated by *ABCD4* mutations and *LMBRD1* mutations ([@j_jomb-2017-0051_ref_035], [@j_jomb-2017-0051_ref_036]). However, a few mutations in the susceptibility genes underscored the importance of more investigations for other influencing polymorphisms in the transportation and metabolic complexes of vitamin B12 and maybe folate pathways. In this case-control study, the results showed a significant association between c.677C\>T variants of the *MTHFR* gene and vitamin B12 deficiency in the studied population. Specifically, the TT genotype and T allele of the *MTHFR-*c.677C\>T variant were found to be significantly associated with low levels of vitamin B12, which is consistent with the recent report by Thuesen et al. ([@j_jomb-2017-0051_ref_013]). Similarly, Shiran et al. ([@j_jomb-2017-0051_ref_015]) and Zittan et al. ([@j_jomb-2017-0051_ref_015]) have shown vitamin B12 deficient individuals homozygous for the TT genotype of *MTHFR-c.677C\>T* variant suffer from endothelial dysfunction and homocysteinemia. In the case of *MTHFR* 1298A\>C variants, our results showed a lack of association with vitamin B12 deficiency. Moreover, the results showed that c.677C\>T and c.1298A\>C variants exhibited linkage disequilibrium for allelic distribution.

Hypothetically, c.677C\>T and c.1298A\>C variants of the *MTHFR* gene result in a decreased MTHFR activity, however, thermolabile protein results only from the c.677C\>T variant. The difference in the functional properties of these variants could be explained by their respective positions in the protein, such as the c.677C\>T is located in the catalytic domain, whereas the 1298A\>C is located in the regulatory domain ([@j_jomb-2017-0051_ref_031]).

In the current study, individuals with TT genotype of the *MTHFR-c.677C\>T* variant showed a simultaneous vitamin B12 deficiency. According to our results and previously reported findings ([@j_jomb-2017-0051_ref_013], [@j_jomb-2017-0051_ref_015]), we propose that vitamin B12 deficiency might be due to mutations and/or polymorphisms in the *MTHFR* gene. The metabolic explanation of the association between B12 deficiency and TT homozygosity is yet to be resolved. However, two explanations have been suggested for this relationship; firstly, abnormal homocysteine metabolism due to the T allele of the *MTHFR-c.677C\>T* variant may cause consumption of vitamin B12; secondly, intestinal absorption of vitamin B12 is genetically associated with the *MTHFR-c.677C\>T* variant. Nevertheless, lifestyle might be another factor that influences the level of vitamin B12 in Jordan. Therefore, more studies are recommended to elucidate the influence of genotypes of the susceptibility genes and lifestyle on the status of vitamin B12 in Jordan. In an unpublished large-scale study (\> 2500 individuals), we demonstrated different prevalence of vitamin B12 level in different geographical locations.

Furthermore, our results showed a significant difference in age between B12 deficient individuals and those of the control group (*p* = 0.006). In addition, the TT genotype of the *MTHFR*-c.677C\>T variant is more frequent in older individuals with vitamin B12 deficiency (*p* = 0.007), which suggests an expected role of this variant in age-onset of vitamin B12 deficiency. This is consistent with the fact that vitamin B12 deficiency is an age-related, slow-developing disorder ([@j_jomb-2017-0051_ref_008], [@j_jomb-2017-0051_ref_037]).

Our results could further help explain higher rates of vitamin B12 deficiency in Jordan. The current cohort is under investigation for other genotypes of transportation complexes with demographic data including folate and homocysteine levels. Collectively, this promising experimental design could initiate the system biology approach that might add to the knowledge of general practitioners and health policy makers to evaluate proper methods of supplementation. Clinically, the *MTHFR* genotyping in B12 deficient individuals could be one of the potential markers for the development of vitamin B12 deficiency. Therefore, deficient or high-risk individuals could have a special protocol of assessment, diet and treatment regimen. It has been reported that supplemental vitamin B12 during pregnancy significantly improved the size-at-birth for children of maternal carriers of the *677TT* genotype ([@j_jomb-2017-0051_ref_038]). Moreover, early genotyping will help in the risk assessment of a certain subset of the population, especially the elderly.

In conclusion, our results showed a significant association between *MTHFR*-c.677C\>T genotypes and vitamin B12 deficiency in a subset of the Jordanian population. On the other hand, the c.1298A\>C variants did not show an association with the deficiency of B12. Further studies are required to elucidate the role of *MTHFR* variants in the metabolism of vitamin B12 and other associated metabolites like folate and homocysteine.
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